According to CordenPharma, the facility will feature multiple manufacturing lines capable of supporting small, medium, and large-scale peptide production with small- to large-scale solid phase peptide synthesis (SPPS) reactors for GLP-1 and non-GLP-1 peptide projects, with a total SPPS reactor capacity of more than 5,000 liters.

The main construction and qualification phase is expected to take place between 2025 and 2027 and start of commercial activities are scheduled to begin in the first half of 2028, creating over 300 new jobs.

Once fully operational, the Switzerland site – together with the ongoing expansions and additional greenfield capacity at the company’s site in Colorado – will significantly enhance the company’s production capabilities.

In their US facility in Boulder, Colorado, both expansions to existing lines and the construction of a new greenfield production area have already begun in parallel to the Switzerland initiative, CordenPharma said. The expansion will more than double the existing SPPS reactor capacity at the site by adding additional 25,000 liters of SPPS capacity – bringing it to a total reactor capacity of >42,000 liters by 2028.

Michael Quirmbach, CEO of CordenPharma, commented: “The new facility is designed to deliver flexible and efficient peptide manufacturing to meet the growing demand of innovative peptide medicines for our customers and ultimately, patients.”